Healthcare / BiotechnologyTokyo
$496.00
-5.00 (-1.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-429.1M · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12.9B
P/E
43.6x
↑EV/EBITDA
12.0x
↓ROE
4.0%
↑Gross Margin
82.1%
↑Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.9%
FCF CAGR
—
FCF margin
-10.8%
FCF / Net income
-1.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.98B · net income $273.1M · FCF $-429.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.98B | $3.98B | $3.11B | $1.90B | $2.92B |
| Net Income | $273.1M | $273.1M | $-495.0M | $-323.7M | $723.4M |
| EBITDA | $985.2M | $985.2M | $86.5M | $-111.8M | $1.00B |
| EPS | — | — | -22.87 | -14.98 | 34.47 |
| Gross Margin | 82.1% | 82.1% | 79.9% | 87.1% | 92.1% |
| Operating Margin | 12.2% | 12.2% | -6.9% | -17.7% | 29.7% |
| Net Margin | 6.9% | 6.9% | -15.9% | -17.0% | 24.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.62 | 0.06 | 0.04 |
| Current Ratio | 6.16 | 6.16 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-429.1M | $-429.1M | $65.0M | $-940.8M | $1.45B |
| Returns | |||||
| ROE | 4.0% | 4.0% | -8.9% | -5.3% | 13.2% |
| Valuation | |||||
| P/E | 43.62 | 43.62 | — | — | 34.93 |
| EV/EBITDA | 11.97 | 11.97 | 97.33 | — | 21.71 |
| P/B | 1.76 | 1.76 | 1.49 | 2.38 | 4.60 |
| Growth & Yield | |||||
| Revenue Growth | 28.1% | 28.1% | 63.5% | -34.8% | — |
| EPS Growth | — | — | -52.7% | -143.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-22.87 → n/d
Residual
-4.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.